SG10202012249YA - Use of markers including filamin a in the diagnosis and treatment of prostate cancer - Google Patents

Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Info

Publication number
SG10202012249YA
SG10202012249YA SG10202012249YA SG10202012249YA SG10202012249YA SG 10202012249Y A SG10202012249Y A SG 10202012249YA SG 10202012249Y A SG10202012249Y A SG 10202012249YA SG 10202012249Y A SG10202012249Y A SG 10202012249YA SG 10202012249Y A SG10202012249Y A SG 10202012249YA
Authority
SG
Singapore
Prior art keywords
diagnosis
treatment
prostate cancer
markers including
filamin
Prior art date
Application number
SG10202012249YA
Inventor
Niven Narain
Vivek Vishnudas
Rangaprasad Sarangarajan
Viatcheslav Akmaev
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG10202012249YA publication Critical patent/SG10202012249YA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
SG10202012249YA 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer SG10202012249YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088931P 2014-12-08 2014-12-08
US201562134956P 2015-03-18 2015-03-18
US201562148294P 2015-04-16 2015-04-16

Publications (1)

Publication Number Publication Date
SG10202012249YA true SG10202012249YA (en) 2021-01-28

Family

ID=56108067

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201704660YA SG11201704660YA (en) 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer
SG10202012249YA SG10202012249YA (en) 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201704660YA SG11201704660YA (en) 2014-12-08 2015-12-08 Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Country Status (10)

Country Link
US (2) US10539566B2 (en)
EP (2) EP4242329A3 (en)
JP (1) JP6759229B2 (en)
KR (1) KR102657306B1 (en)
CN (1) CN107428821B (en)
AU (1) AU2015360694B2 (en)
CA (1) CA2970143A1 (en)
IL (1) IL252766B (en)
SG (2) SG11201704660YA (en)
WO (1) WO2016094425A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268978A1 (en) * 2015-03-12 2018-01-17 Thermo Finnigan LLC Methods for data-dependent mass spectrometry of mixed biomolecular analytes
EP3281151B1 (en) * 2015-04-10 2023-03-29 President and Fellows of Harvard College Methods and devices for live cell imaging analysis
WO2018009834A1 (en) * 2016-07-07 2018-01-11 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
EP3493819B1 (en) 2016-08-05 2022-05-11 The Research Foundation for The State University of New York Keratin 17 as a biomarker for bladder cancer
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
US10759850B2 (en) 2016-11-01 2020-09-01 Berg Llc Filamin A binding proteins and uses thereof
WO2018189292A1 (en) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarkers of castration-resistant prostatic cells
JP7165210B2 (en) * 2018-05-24 2022-11-02 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Quantitative analysis of proteins
CN108624691A (en) * 2018-06-22 2018-10-09 杭州西合精准医疗科技有限公司 A kind of marker and its application for judging prostatic disorders
EP3821031A4 (en) * 2018-07-12 2022-07-20 Berg LLC Methods for differentiating benign prostatic hyperplasia from prostate cancer
JP7442769B2 (en) 2018-10-09 2024-03-05 アイベックス バイオサイエンシーズ， インコーポレイテッド Antibodies against filamin A and their therapeutic uses
US20210080466A1 (en) * 2019-06-26 2021-03-18 Berg Llc Markers for the diagnosis of prostate cancer
US11042980B1 (en) * 2020-01-02 2021-06-22 Robert Edwin Douglas Method and apparatus for using quantative and qualitative data from medical imaging examinations for precise dosing regimen
CN114134223B (en) * 2021-12-02 2022-10-11 青岛市中心血站 Blood detection kit for hepatitis C virus-related liver fibrosis
CN114155956B (en) * 2021-12-02 2022-09-20 首都医科大学附属北京地坛医院 System and method for predicting blood vessel invasion probability of primary liver cancer patient incapable of being resected by surgery
CN114882996B (en) * 2022-03-17 2023-04-07 深圳大学 Hepatocellular carcinoma CK19 and MVI prediction method based on multitask learning
CN117843753A (en) * 2022-10-04 2024-04-09 中国医学科学院药物研究所 Keratin YK93-2, preparation method, pharmaceutical composition and application thereof

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4786600A (en) 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
JP2846018B2 (en) 1988-01-21 1999-01-13 ジェネンテク，インコーポレイテッド Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE3924454A1 (en) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg THE APPLICATION OF DNA AND DNA TECHNOLOGY FOR THE CONSTRUCTION OF NETWORKS FOR USE IN CHIP CONSTRUCTION AND CHIP PRODUCTION (DNA CHIPS)
DE3938907C2 (en) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Means for storing and suspending cells, in particular erythrocytes
DE3942999C2 (en) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Procedure for the detection of malignant diseases
IL103674A0 (en) 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
ATE463573T1 (en) 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
EP0618925B2 (en) 1991-12-24 2012-04-18 Isis Pharmaceuticals, Inc. Antisense oligonucleotides
DE4208422A1 (en) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Method for the detection of micrometastases of ectodermal or endodermal tumors
AU5298393A (en) 1992-10-08 1994-05-09 Regents Of The University Of California, The Pcr assays to determine the presence and concentration of a target
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
WO1995000530A1 (en) 1993-06-25 1995-01-05 Affymax Technologies N.V. Hybridization and sequencing of nucleic acids
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
KR100230718B1 (en) 1994-03-16 1999-11-15 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 Isothermal strand displacement nucleic acid amplification
AU2522095A (en) 1994-05-19 1995-12-18 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US5658734A (en) 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
ATE471150T1 (en) 1996-03-26 2010-07-15 Kopreski Michael S METHODS USING EXTRACELLURAER RNA EXTRACTED FROM PLASMA OR SERUM FOR DIAGNOSTIC MONITORING OR EVALUATION OF CANCER
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
WO1998002582A2 (en) 1996-07-16 1998-01-22 Gen-Probe Incorporated Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific t¿m?
US6207380B1 (en) 1997-09-15 2001-03-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
ATE249236T1 (en) 1998-10-22 2003-09-15 Curagen Corp PREDICTIVE AND THERAPEUTIC FOR KIDNEY DISEASE GENES AND PROTEINS
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6607885B1 (en) 1999-10-15 2003-08-19 E. I. Du Pont De Nemours And Company Method for high-density microarray medicated gene expression profiling
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
EP1274861B1 (en) 2000-03-27 2009-12-23 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
JP2004512029A (en) 2000-08-16 2004-04-22 カイロン　コーポレイション Human genes and gene expression products
AU2001294859A1 (en) 2000-09-29 2002-04-08 Molecular Probes, Inc. Modified carbocyanine dyes and their conjugates
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
JP2004529630A (en) 2001-03-01 2004-09-30 エピゲノミクス アーゲー Methods for developing diagnostic and therapeutic gene panels based on gene expression and methylation status
ES2486265T3 (en) 2002-03-13 2014-08-18 Genomic Health, Inc. Obtaining gene expression profile in biopsied tumor tissues
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
EP1510587B1 (en) 2002-05-21 2011-07-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
AU2003277016A1 (en) 2002-09-26 2004-05-04 Atomix, Llc Roto-dynamic fluidic system
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US6974874B2 (en) 2002-10-31 2005-12-13 Bayer Materialscience Llc Reduction of monomer content and stabilization of polyaziridines
US20040109863A1 (en) 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (en) 2002-12-19 2004-07-08 Ivonex Gmbh separation process
AU2003299818A1 (en) 2002-12-20 2004-07-22 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2004076614A2 (en) 2003-02-27 2004-09-10 Bernd Hinzmann Human nucleic acid sequences obtained from prostatic carcinomas
EP1604014A4 (en) 2003-03-20 2008-03-26 Dana Farber Cancer Inst Inc Gene expression in breast cancer
JP2007507222A (en) 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド Gene expression markers for predicting response to chemotherapy
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
ITPD20030264A1 (en) 2003-10-30 2005-04-30 Xeptagen Spa HIGHLY SPECIFIC DIAGNOSIS METHOD FOR NEOPLASIA
CN1743849A (en) 2004-09-03 2006-03-08 上海透景生命科技有限公司 Multi tumour tag parallel detecting method and kit
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) * 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
NZ554895A (en) 2004-11-03 2009-06-26 Almac Diagnostics Ltd Transcriptome microarray technology and methods of using the same
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
ATE477495T1 (en) 2005-03-16 2010-08-15 Osi Pharm Inc BIOLOGICAL MARKERS PREDICTIVE OF CANCER RESPONSIVENESS TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
EP2270226B1 (en) 2005-03-31 2016-05-18 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
US8609345B2 (en) 2005-05-25 2013-12-17 Expression Pathology Incorporated Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2006127860A2 (en) 2005-05-25 2006-11-30 Expression Pathology, Inc. Multiplex method for increased proteomic coverage from histopathologically processed biological samples using liquid tissue preparations
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1734118A1 (en) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
US20070122856A1 (en) 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Tissue diagnostics for ovarian cancer
US20080305558A1 (en) 2005-12-19 2008-12-11 Ruth Louise Loveday Cancer Screening Test
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (en) 2006-04-11 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー Rapid measurement method of cytokeratin 19 (CK19) mRNA, and primer and probe therefor
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
US7901902B2 (en) 2006-07-27 2011-03-08 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
US8524493B2 (en) 2006-09-07 2013-09-03 Centre Hospitalier Universitaire De Montpellier Released cytokeratins as markers for epithelial cells
EP2094719A4 (en) 2006-12-19 2010-01-06 Genego Inc Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008121307A2 (en) 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
EP2559771A3 (en) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
US8889361B2 (en) 2007-09-19 2014-11-18 The Research Foundation For The State University Of New York Gene expression signatures in enriched tumor cell samples
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
CA2708153C (en) 2007-12-04 2017-09-26 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
ATE524740T1 (en) 2007-12-10 2011-09-15 Hoffmann La Roche SEPRASE AS A CANCER MARKER
US20110053157A1 (en) 2008-02-01 2011-03-03 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
MX2011000451A (en) 2008-07-16 2011-10-12 Dana Farber Cancer Inst Inc Signatures and pcdeterminants associated with prostate cancer and methods of use thereof.
US9127078B2 (en) 2008-07-21 2015-09-08 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
IT1391619B1 (en) 2008-11-04 2012-01-11 Silicon Biosystems Spa METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
CN102209899B (en) 2008-11-12 2014-05-07 霍夫曼-拉罗奇有限公司 Pacap as a marker for cancer
EP2370813A4 (en) 2008-12-04 2012-05-23 Univ California Materials and methods for determining diagnosis and prognosis of prostate cancer
JP5368579B2 (en) 2008-12-22 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ARMET as a marker for cancer
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
JP2012100536A (en) 2009-03-02 2012-05-31 Genescience Co Ltd Genetic testing method for cancer by analysis of expression of cancer-relating gene utilizing monocyte contained in blood sample
US20110311443A1 (en) 2009-03-06 2011-12-22 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
EP2421900A1 (en) 2009-04-24 2012-02-29 Alper Biotech, Llc Monoclonal antibodies against pcbp-1 antigens, and uses therefor
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
WO2011040532A1 (en) 2009-10-02 2011-04-07 学校法人 久留米大学 Method for predicting therapeutic effect of immunotherapy on cancer patient and/or prognosis after immunotherapy, and gene set and kit to be used therein
EP2309262A1 (en) * 2009-10-06 2011-04-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for quantifying biomolecules
WO2011053837A1 (en) 2009-10-29 2011-05-05 King Kutter, Inc. Stump cutter
EP2335838B1 (en) 2009-12-18 2012-09-26 Deutsche Post AG Sorting system and method using a portable device
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
FR2957821B1 (en) 2010-03-24 2014-08-29 Inst Francais Du Petrole NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS
BR112012025593A2 (en) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings circulating biomarkers for disease
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
EP2390665A1 (en) 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US9040464B2 (en) 2010-08-16 2015-05-26 Mount Sinai Hosptial Markers of the male urogenital tract
JP2013540995A (en) 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． Circulating biomarkers for disease
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN103476428B (en) 2010-09-09 2016-10-26 北京同为时代生物技术有限公司 For diagnosing blood markers thing and the monoclonal antibody thereof of epitheliogenic cancerg
EP2616543A1 (en) 2010-09-15 2013-07-24 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
WO2012077139A1 (en) 2010-12-06 2012-06-14 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
WO2012083338A1 (en) 2010-12-24 2012-06-28 Map Diagnostics Pty Ltd. Selective reaction monitoring (srm) derived protein profiles for cancer and other pathologic entities
EP2668503B1 (en) 2011-01-28 2015-06-24 F.Hoffmann-La Roche Ag Combinatorial biomarkers for clinical applications in lung cancer patient management
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
PE20180776A1 (en) 2011-03-02 2018-05-07 Berg Llc CELL-BASED INTERROGATORY TESTS AND THE USE OF THEM
KR101320633B1 (en) 2011-05-25 2013-10-30 엠앤디 (주) Method of providing information for diagnosis of cancer using quantitative realtime PCR and diagnostic kit comprising thereof
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
WO2012149522A1 (en) * 2011-04-28 2012-11-01 Baylor College Of Medicine Recurrent chimeric rnas enriched in human prostate cancer as biomarkers
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2551673B1 (en) 2011-07-26 2016-01-20 Universidad de Salamanca Methods for the detection of cancer infiltration of the central nervous system
JP2014522993A (en) * 2011-08-08 2014-09-08 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． Biomarker compositions and methods
EP2756298A4 (en) 2011-09-12 2015-08-12 Creatics Llc Non-invasive methods of detecting target molecules
EP2823306A4 (en) 2012-03-09 2015-11-11 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
ES2875535T3 (en) 2012-03-29 2021-11-10 Biogen Ma Inc Biomarkers for use in Integrin Therapy Applications
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
EP2838298B1 (en) 2012-05-09 2019-07-10 Huawei Technologies Co., Ltd. Method and device for data transmission
WO2013173476A1 (en) * 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of cancer
ES2720763T3 (en) * 2012-06-27 2019-07-24 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
TWI468519B (en) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
EP2895864B1 (en) 2012-09-17 2021-03-10 AIT Austrian Institute of Technology GmbH Colon cancer diagnostic method and means
WO2014116170A1 (en) * 2013-01-22 2014-07-31 Neoproteomics Ab Platelet biomarkers in cancer diagnosis
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
US20140296096A1 (en) * 2013-03-27 2014-10-02 Oslo Universitetssykehus Hf Prostate cancer markers and uses thereof
SE538211C2 (en) 2013-04-05 2016-04-05 Idl Biotech Ab Method for detecting cytokeratin 8, 18 and / or 19 and / or soluble fragments thereof
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
EP3047270A4 (en) 2013-09-20 2017-07-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain

Also Published As

Publication number Publication date
EP3230314B1 (en) 2023-05-03
JP2018506045A (en) 2018-03-01
EP4242329A3 (en) 2023-10-25
IL252766B (en) 2021-07-29
US20200333344A1 (en) 2020-10-22
KR20170092671A (en) 2017-08-11
US20160258958A1 (en) 2016-09-08
KR102657306B1 (en) 2024-04-12
EP4242329A2 (en) 2023-09-13
EP3230314A4 (en) 2018-06-06
CA2970143A1 (en) 2016-06-16
AU2015360694B2 (en) 2021-10-14
EP3230314A1 (en) 2017-10-18
AU2015360694A1 (en) 2017-06-29
CN107428821B (en) 2022-06-24
US10539566B2 (en) 2020-01-21
IL252766A0 (en) 2017-08-31
JP6759229B2 (en) 2020-09-23
WO2016094425A1 (en) 2016-06-16
SG11201704660YA (en) 2017-07-28
CN107428821A (en) 2017-12-01

Similar Documents

Publication Publication Date Title
IL252766B (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL251630A0 (en) Combination therapy for use in cancer therapy
GB201403093D0 (en) Therapeutic compounds and their use
SG11201701035SA (en) Cancer diagnosis and therapy
HRP20190888T8 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
IL276733A (en) Use of eribulin in the treatment of cancer
HK1209792A1 (en) Use of markers in the diagnosis and treatment of prostate cancer
IL249741B (en) Identification of cancer stem cells markers and use of same for diagnosis and treatment
GB201409363D0 (en) Skin cancer treatment
PT3258931T (en) Use of cabazitaxel in the treatment of prostate cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
IL251825A0 (en) Cancer and skin lesion treatment
IL273054A (en) Abx196 for use in the treatment of bladder cancer
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201410387D0 (en) Compounds and their therapeutic use
GB201409978D0 (en) Novel compounds and their use in therapy
GB201403496D0 (en) Compounds and their therapeutic use